Celldex Therapeutics, Inc. - Common Stock (CLDX) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2018 to Q4 2025

Type / Class
Equity / Common Stock
Symbol
CLDX on Nasdaq
Shares outstanding
66,226,295
Price per share
$26.85
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
73,373,461
Total reported value
$1,992,601,373
% of total 13F portfolios
0%
Share change
+1,659,821
Value change
+$46,200,183
Number of holders
181
Price from insider filings
$26.85
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Celldex Therapeutics, Inc. - Common Stock (CLDX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WELLINGTON MANAGEMENT GROUP LLP 12% +10% $219,442,153 +$18,600,852 8,079,608 +9.3% Wellington Management Group LLP 31 Dec 2025
Kynam Capital Management, LP 9.8% +27% $136,045,000 +$30,051,147 6,500,000 +28% Kynam Capital Management, LP 31 Mar 2025
FMR LLC 7.3% $101,670,991 4,857,668 FMR LLC 31 Dec 2024
BlackRock, Inc. 7.3% -12% $100,867,802 -$13,842,621 4,819,293 -12% BlackRock, Inc. 31 Mar 2025
Point72 Asset Management, L.P. 6.7% $90,854,558 4,464,400 Point72 Asset Management, L.P. 02 Jul 2025
Bellevue Group AG 5.4% $93,589,097 3,617,669 Bellevue Group AG 18 Aug 2025
STATE STREET CORP 5.1% $92,281,885 3,397,713 STATE STREET CORPORATION 31 Dec 2025
Commodore Capital LP 4.6% -8% $78,343,026 -$8,321,474 3,028,335 -9.6% Commodore Capital LP 30 Sep 2025
PRICE T ROWE ASSOCIATES INC /MD/ 3.6% -36% $61,640,475 -$30,382,633 2,382,701 -33% T. Rowe Price Associates, Inc. 30 Sep 2025
EVENTIDE ASSET MANAGEMENT, LLC 2% $30,459,938 1,356,186 Eventide Asset Management, LLC 30 Jun 2025

As of 31 Dec 2025, 181 institutional investors reported holding 73,373,461 shares of Celldex Therapeutics, Inc. - Common Stock (CLDX). This represents 111% of the company’s total 66,226,295 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Celldex Therapeutics, Inc. - Common Stock (CLDX) together control 91% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
WELLINGTON MANAGEMENT GROUP LLP 12% 8,079,608 +39% 0.04% $219,442,154
Kynam Capital Management, LP 9% 5,943,180 -2.6% 11% $161,416,769
BlackRock, Inc. 8.2% 5,451,815 -0.98% 0% $148,071,294
FMR LLC 7.4% 4,907,469 -1.1% 0.01% $133,286,863
VANGUARD GROUP INC 6.1% 4,027,407 +1.8% 0% $109,384,374
Bellevue Group AG 5.5% 3,617,669 +1.7% 1.9% $98,255,890
STATE STREET CORP 5.1% 3,397,713 +20% 0% $92,281,885
Commodore Capital LP 3.9% 2,565,000 -15% 4.6% $69,665,400
PRICE T ROWE ASSOCIATES INC /MD/ 3.1% 2,039,705 -14% 0.01% $55,399,000
Deep Track Capital, LP 2.9% 1,900,738 -5% 1.2% $51,624,044
BRAIDWELL LP 2.8% 1,858,109 +214% 1.6% $50,466,240
Point72 Asset Management, L.P. 2.7% 1,758,357 -55% 0.07% $47,756,976
EVENTIDE ASSET MANAGEMENT, LLC 2.5% 1,642,559 -12% 0.7% $44,607,415
GEODE CAPITAL MANAGEMENT, LLC 2.5% 1,627,529 -1.2% 0% $44,211,330
Eversept Partners, LP 2.2% 1,434,725 +24% 2.2% $38,967,131
MILLENNIUM MANAGEMENT LLC 1.8% 1,212,705 +24% 0.02% $32,937,068
NOVO HOLDINGS A/S 1.8% 1,200,000 0% 2.5% $32,592,000
Vestal Point Capital, LP 1.8% 1,165,000 -3.3% 1.2% $31,641,400
GOLDMAN SACHS GROUP INC 1.6% 1,068,131 +3.8% 0% $29,010,438
Polar Capital Holdings Plc 1.5% 1,008,163 -22% 0.13% $27,381,707
Pictet Asset Management Holding SA 1.5% 968,616 -20% 0.03% $26,307,611
Fisher Asset Management, LLC 1.4% 937,158 +1.1% 0.01% $25,453,210
Elmind Capital, LP 1.3% 865,000 0% 6.9% $23,493,400
AMERICAN CENTURY COMPANIES INC 1.3% 855,226 +4.9% 0.01% $23,227,976
Rock Springs Capital Management LP 1% 692,538 -4% 0.97% $18,809,332

Institutional Holders of Celldex Therapeutics, Inc. - Common Stock (CLDX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 73,373,461 $1,992,601,373 +$46,200,183 $27.16 181
2025 Q3 70,729,708 $1,829,814,017 -$41,022,042 $25.87 180
2025 Q2 72,686,329 $1,479,214,886 -$18,971,957 $20.35 178
2025 Q1 73,628,376 $1,336,550,222 -$25,518,368 $18.15 170
2024 Q4 73,686,767 $1,861,792,917 -$10,935,353 $25.27 172
2024 Q3 71,809,989 $2,440,639,326 +$62,002,971 $33.99 174
2024 Q2 69,594,154 $2,575,716,559 +$1,332,092 $37.01 181
2024 Q1 69,311,318 $2,908,781,828 +$362,625,073 $41.97 196
2023 Q4 60,989,057 $2,418,831,729 +$410,573,840 $39.66 162
2023 Q3 50,572,705 $1,391,763,899 +$5,531,719 $27.52 140
2023 Q2 50,188,683 $1,702,972,802 +$19,493,416 $33.93 148
2023 Q1 49,503,692 $1,779,547,358 +$24,122,749 $35.98 158
2022 Q4 48,677,430 $2,169,609,749 -$9,316,822 $44.57 163
2022 Q3 49,338,461 $1,386,923,833 +$32,333,656 $28.11 146
2022 Q2 48,218,738 $1,300,004,065 -$45,672,202 $26.96 146
2022 Q1 49,602,527 $1,689,417,077 +$106,143,717 $34.06 157
2021 Q4 46,338,765 $1,790,195,856 +$97,400,922 $38.64 170
2021 Q3 43,227,306 $2,333,703,184 +$430,296,249 $53.99 156
2021 Q2 35,559,554 $1,189,106,240 +$60,325,552 $33.44 127
2021 Q1 34,503,199 $709,497,850 -$40,255,166 $20.60 109
2020 Q4 36,816,222 $645,045,236 +$72,177,637 $17.52 120
2020 Q3 32,156,087 $476,873,776 +$67,764,471 $14.83 82
2020 Q2 27,786,246 $361,216,517 +$310,785,532 $13.00 63
2020 Q1 3,949,694 $6,557,892 +$7,227 $1.66 32
2019 Q4 3,904,189 $8,706,543 +$447,617 $2.23 34
2019 Q3 3,708,146 $7,895,004 +$465,004 $2.13 40
2019 Q2 3,466,005 $9,286,115 +$2,108,302 $2.68 39
2019 Q1 2,603,854 $12,809,043 +$12,313,782 $4.92 39
2018 Q4 100,357 $20,000 +$20,000 $0.20 1